
Overview
James T. Handa, M.D., is Chief of the Retina Division and the Robert Bond Welch, M.D., Professor of Ophthalmology at the Wilmer Eye Institute. He specializes in medical and surgical management of complex vitreoretinal diseases such as age-related macular degeneration, diabetic retinopathy, retinal detachment, retinopathy of prematurity and other pediatric retinal diseases. He also has expertise in intraocular oncology and manages patients with choroidal melanomas and metastatic tumors of the eye. Not only is he a highly skilled surgeon and clinician, but he also devotes significant effort to research related to the early causes of age-related macular degeneration using molecular pathological approaches to understand how the eye transforms from normal aging to early disease. He has been funded by the National Eye Institute for the last 19 years, and he currently holds two R01 awards for his work in AMD. He has also been funded by the Thome Foundation, Research to Prevent Blindness, Fight for Sight and the American Health Assistance Foundation. His other research focuses on surgical innovation using an integrated robotic surgical system. Dr. Handa is currently the Wilmer Eye Institute’s implanting surgeon for the Argus II retinal chip implant, which was recently approved by the FDA after Dr. Handa participated in the clinical trial leading to its approval.
Dr. Handa is highly rated in 12 conditions, according to our data. His top areas of expertise are Melanoma of the Eye, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Metastatic Uveal Melanoma, and Vitrectomy.
His clinical research consists of co-authoring 139 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.
Residency
Specialties
Licenses
Board Certifications
Fellowships
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
1800 Orleans Street, Maumenee Lobby, Maumenee Lobby, Baltimore, MD 21287
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
Skip Viragh Outpatient Cancer Center
Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is highly rated in 19 conditions, according to our data. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.
Office
Taofeek Owonikoko is a Hematologist and an Oncologist in Baltimore, Maryland. Dr. Owonikoko is highly rated in 18 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.
Sidney Kimmel Comprehensive Cancer Center
Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is highly rated in 22 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.
Frequently Asked Questions about Dr. Jim Handa
How do I make an appointment with Dr. Jim Handa?
You can book an appointment with Dr. Jim Handa by calling their office at 410-955-5080. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Jim Handa a top-rated expert for Melanoma of the Eye?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jim Handa is classified as an Elite expert for Melanoma of the Eye, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Jim Handa specialize in?
While Dr. Jim Handa is a Oncology, they have specific expertise in Melanoma of the Eye, Late-Onset Retinal Degeneration, and Age-Related Macular Degeneration (ARMD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.
Does Dr. Jim Handa participate in research or clinical trials?
Yes. Dr. Jim Handa has published 139 articles and abstracts on conditions like Melanoma of the Eye. You can view a list of Dr. Jim Handa's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. Jim Handa accept my insurance?
Dr. Jim Handa accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 410-955-5080 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- Age-Related Macular Degeneration (ARMD)
- Late-Onset Retinal Degeneration
- Melanoma of the EyeDr. Handa isElite. Learn about Melanoma of the Eye.
- Distinguished
- Choroid Plexus CarcinomaDr. Handa isDistinguished. Learn about Choroid Plexus Carcinoma.
- Metastatic Uveal MelanomaDr. Handa isDistinguished. Learn about Metastatic Uveal Melanoma.
- Retinal DetachmentDr. Handa isDistinguished. Learn about Retinal Detachment.
- Advanced
- Geographic AtrophyDr. Handa isAdvanced. Learn about Geographic Atrophy.
- HyphemaDr. Handa isAdvanced. Learn about Hyphema.
- Retinopathy Pigmentary Mental Retardation
- Stargardt Macular DegenerationDr. Handa isAdvanced. Learn about Stargardt Macular Degeneration.
- Uveal MelanomaDr. Handa isAdvanced. Learn about Uveal Melanoma.
- VitrectomyDr. Handa isAdvanced. Learn about Vitrectomy.
- Experienced
- Adult-Onset Vitelliform Macular Dystrophy (AVMD)
- CataractDr. Handa isExperienced. Learn about Cataract.
- Cone DystrophyDr. Handa isExperienced. Learn about Cone Dystrophy.
- Cone Rod Dystrophy Amelogenesis Imperfecta
- Cone-Rod DystrophyDr. Handa isExperienced. Learn about Cone-Rod Dystrophy.
- Diabetic Macular Edema (DME)Dr. Handa isExperienced. Learn about Diabetic Macular Edema (DME).

